A glimpse into the future of model-informed drug discovery and development Publication A glimpse into the future of model-informed drug discovery and development Explore the future of Model-Informed Drug Development (MIDD), including advances in pharmacometrics, PBPK, QSP, precision…Certara2026年8月28日
Transforming drug interaction evaluation workflows with DIDB Webinar Transforming drug interaction evaluation workflows with DIDB Ichiko Petrie, PharmD2026年8月14日
Managing drug-drug interaction (DDI) risk for patients in clinical trials White Paper Managing drug-drug interaction (DDI) risk for patients in clinical trials Discover how DIDB® helps clinical teams assess drug-drug interaction risk, develop prohibited medication lists, &…Katie Owens, PhD2026年8月12日
Assessing Cross-Version Simcyp Simulator Prediction Performance Using a Bioequivalence Framework to Support EMA Qualification Poster Assessing Cross-Version Simcyp Simulator Prediction Performance Using a Bioequivalence Framework to Support EMA Qualification See how Simcyp Simulator V20–V24 DDI predictions were shown equivalent to the EMA-qualified V19 using…Certara2026年7月24日
Integrated mechanistic modeling approaches in oncology drug development Webinar Integrated mechanistic modeling approaches in oncology drug development Certara2026年7月8日
Mechanistic MIDD: Achieving Regulatory Success Through Strong Scientific Foundations Live Events Mechanistic MIDD: Achieving Regulatory Success Through Strong Scientific Foundations 2026年6月30日 - 12:00 PM – 2:00 PMCertara2026年6月10日
The Modeling Advantage: How Forward-Thinking Sponsors Are Moving Faster, De-Risking Earlier, and Winning with Regulators On-Demand Webinar The Modeling Advantage: How Forward-Thinking Sponsors Are Moving Faster, De-Risking Earlier, and Winning with Regulators Learn how PBPK and QSP modeling support regulatory confidence, accelerate drug development, and align with…Certara2026年5月26日
Simcyp Focused Workshop: DDI (Predicting and evaluating complex DDIs) Japan Live Events Simcyp Focused Workshop: DDI (Predicting and evaluating complex DDIs) Japan Certara2026年5月20日
Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation Publication Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation This study evaluated how the leukemia drug ziftomenib behaves in the body and whether different…Certara2026年5月7日
DIDB® Concomitant Meds Navigator Fact Sheet DIDB® Concomitant Meds Navigator Explore the Concomitant Meds Navigator withing DIDB - An evidence-based tool within DIDB that helps…Certara2026年4月27日